(IN BRIEF) Merck, a prominent science and technology company, has entered into a strategic partnership with Jiangsu Hengrui Pharmaceuticals. This…
TOP-LINE DATA FROM REMIX-1 AND REMIX-2 STUDIES DEMONSTRATE SIGNIFICANT SYMPTOM IMPROVEMENT (IN BRIEF) Novartis has unveiled promising results from Phase…
Not intended for U.S. and UK Media (IN BRIEF) The European Medicines Agency's Committee for Medicinal Products for Human Use…
Libtayo is the first investigational medicine to show a clinical benefit in advanced basal cell carcinoma following treatment with a…
Approval based on COMBI-AD study demonstrating greater than 50% reduction in risk of disease recurrence or death in stage III…
SOLAR-1 evaluated BYL719 plus fulvestrant vs. fulvestrant alone in HR+/HER2- advanced breast cancer patients with PIK3CA mutations who progressed on…
Lynparza is the first PARP inhibitor approved in Japan Lynparza tablets approved as maintenance treatment for women with platinum-sensitive relapsed…
Turku, 29-5-2013 — /europawire.eu/ — Biotie Therapies today announced the start of a Phase 2 clinical study evaluating nepicastat (SYN117) in…